Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Evolus, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEWPORT BEACH, CALIF.--(BUSINESS WIRE)--EVOLUS, INC. (NASDAQ: EOLS), A GLOBAL PERFORMANCE BEAUTY COMPANY WITH A FOCUS ON BUILDING AN AESTHETIC PORTFOLIO OF CONSUMER BRANDS, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2026. THE INCREASING MOMENTUM OF OUR PORTFOLIO FOCUS HAS RESULTED IN EVOLUS GAINING SIGNIFICANT SHARE ACROSS INJECTABLE AESTHETICS DURING THE SECOND QUARTER, SUPPORTED BY DOUBLE-DIGIT GROWTH FOR JEUVEAU AND ACCELERATING ADOPTION OF EVOLYSSE, SAID.

EVOLUS REPORTS STRONG SECOND QUARTER 2026 FINANCIAL RESULTS; DELIVERS THIRD CONSECUTIVE QUARTER OF POSITIVE ADJUSTED EBITDA AND RAISES FULL-YEAR 2026 FINANCIAL OUTLOOK

NEWPORT BEACH, CALIF.--(BUSINESS WIRE)--EVOLUS, INC. (NASDAQ: EOLS), A GLOBAL PERFORMANCE BEAUTY COMPANY WITH A FOCUS ON BUILDING AN AESTHETIC PORTFOLIO OF CONSUMER BRANDS, TODAY ANNOUNCED IT HAS EXPANDED ITS PARTNERSHIP WITH SYMATESE THROUGH AN AMENDMENT TO THE COMPANIES' EXISTING LICENSING AND DISTRIBUTION AGREEMENT, PROVIDING EVOLUS WITH THE EXCLUSIVE RIGHTS TO COMMERCIALIZE THE ESTYME (PRONOUNCED ESTEEM) COLLECTION OF INJECTABLE HYALURONIC ACID (HA) GELS IN CANADA, AUSTRALIA, AND NEW ZEA.

EVOLUS EXPANDS STRATEGIC PARTNERSHIP WITH SYMATESE TO COMMERCIALIZE ESTYME IN CANADA, AUSTRALIA, AND NEW ZEALAND

NEWPORT BEACH, CALIF.--(BUSINESS WIRE)--EVOLUS, INC. (NASDAQ: EOLS), A PERFORMANCE BEAUTY COMPANY WITH A FOCUS ON BUILDING AN AESTHETIC PORTFOLIO OF CONSUMER BRANDS, TODAY ANNOUNCED THAT IT WILL REPORT ITS SECOND QUARTER 2026 FINANCIAL RESULTS ON WEDNESDAY, AUGUST 5, 2026, AFTER THE U.S. FINANCIAL MARKETS CLOSE.EVOLUS MANAGEMENT WILL HOST A CONFERENCE CALL AND LIVE WEBCAST TO DISCUSS THESE RESULTS AT 4:30 P.M. ET THAT SAME DAY. A QUESTION-AND-ANSWER SESSION WILL FOLLOW MANAGEMENT'S REMARKS.TO PA.

EVOLUS TO REPORT SECOND QUARTER FINANCIAL RESULTS ON AUGUST 5, 2026

NEWPORT BEACH, CALIF.--(BUSINESS WIRE)--EVOLUS, INC. (NASDAQ: EOLS), A PERFORMANCE BEAUTY COMPANY WITH A FOCUS ON BUILDING AN AESTHETIC PORTFOLIO OF CONSUMER BRANDS, TODAY REPORTED THE GRANT DURING APRIL 2026 TO JULY 2026 OF AN AGGREGATE OF 115,000 RESTRICTED STOCK UNITS (RSUS) OF THE COMPANY'S COMMON STOCK TO 38 NEWLY HIRED NON-EXECUTIVE EMPLOYEES OF THE COMPANY. THE AWARDS WERE APPROVED BY THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS UNDER THE EVOLUS' 2023 INDUCEMENT INCENTIV.

EVOLUS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

NEWPORT BEACH, CALIF.--(BUSINESS WIRE)--EVOLUS, INC. (NASDAQ: EOLS), A GLOBAL PERFORMANCE BEAUTY COMPANY WITH A FOCUS ON BUILDING AN AESTHETIC PORTFOLIO OF CONSUMER BRANDS, TODAY ANNOUNCED IT HAS ENTERED INTO AN EXCLUSIVE LICENSING AND DISTRIBUTION AGREEMENT WITH IBSA, A SWISS MULTINATIONAL PHARMACEUTICAL COMPANY, TO DEVELOP AND COMMERCIALIZE PROFHILO IN THE UNITED STATES. PROFHILO IS THE MARKET-LEADING INJECTABLE IN EUROPE FOR SKIN QUALITY, WITH GLOBAL BRAND RECOGNITION AND AVAILABILITY IN M.

EVOLUS ANNOUNCES PARTNERSHIP WITH IBSA TO DEVELOP AND COMMERCIALIZE MARKET-LEADING PROFHILO IN THE UNITED STATES, EXPANDING ITS INJECTABLE PORTFOLIO INTO SKIN QUALITY

NEWPORT BEACH, CALIF.--(BUSINESS WIRE)--EVOLUS, INC. (NASDAQ: EOLS), A PERFORMANCE BEAUTY COMPANY WITH A FOCUS ON BUILDING AN AESTHETIC PORTFOLIO OF CONSUMER BRANDS, TODAY ANNOUNCED MEMBERS OF ITS MANAGEMENT TEAM WILL PARTICIPATE IN A FIRESIDE CHAT AND INVESTOR MEETINGS AT THE UPCOMING JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN NEW YORK CITY. THE FIRESIDE CHAT WILL TAKE PLACE ON THURSDAY, JUNE 4TH, 2026, AT 12:50 PM ET. THE FIRESIDE CHAT CAN BE ACCESSED ON THE INVESTOR RELATIONS PAGE OF THE EVOL.

EVOLUS TO PARTICIPATE IN THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE

NEWPORT BEACH, CALIF.--(BUSINESS WIRE)--EVOLUS, INC. (NASDAQ: EOLS), A GLOBAL PERFORMANCE BEAUTY COMPANY WITH A FOCUS ON BUILDING AN AESTHETIC PORTFOLIO OF CONSUMER BRANDS, TODAY ANNOUNCED THAT THE COMMERCIAL LAUNCH OF ESTYME (PRONOUNCED ESTEEM), ITS INJECTABLE HYALURONIC ACID (HA) GEL COLLECTION IN EUROPE, IS SCHEDULED FOR MAY 16TH, MARKING THE COMPANY'S ENTRY INTO THE INTERNATIONAL DERMAL FILLER MARKET. THE ESTYME COLLECTION INCLUDES FOUR INJECTABLE HA GELS THAT WILL COVER A WIDE RANGE OF.

EVOLUS ANNOUNCES COMMERCIAL LAUNCH OF ESTYME INJECTABLE HYALURONIC ACID GELS IN EUROPE

NEWPORT BEACH, CALIF.--(BUSINESS WIRE)--EVOLUS, INC. (NASDAQ: EOLS), A GLOBAL PERFORMANCE BEAUTY COMPANY WITH A FOCUS ON BUILDING AN AESTHETIC PORTFOLIO OF CONSUMER BRANDS, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026. WE STARTED 2026 WITH A SECOND CONSECUTIVE QUARTER OF POSITIVE ADJUSTED EBITDA, DELIVERING PROFITABILITY1 IN WHAT IS SEASONALLY OUR LOWEST REVENUE QUARTER, SAID DAVID MOATAZEDI, PRESIDENT AND CHIEF EXECUTIVE OFFICER OF EVOLUS. THIS PERFORMANC.

EVOLUS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS; COMPANY DELIVERS SECOND CONSECUTIVE QUARTER OF POSITIVE ADJUSTED EBITDA AND REAFFIRMS FULL-YEAR OUTLOOK

NEWPORT BEACH, CALIF.--(BUSINESS WIRE)--EVOLUS, INC. (NASDAQ: EOLS), A PERFORMANCE BEAUTY COMPANY WITH A FOCUS ON BUILDING AN AESTHETIC PORTFOLIO OF CONSUMER BRANDS, TODAY ANNOUNCED THAT IT WILL REPORT ITS FIRST QUARTER 2026 FINANCIAL RESULTS ON MONDAY, MAY 4, 2026, AFTER THE U.S. FINANCIAL MARKETS CLOSE. EVOLUS MANAGEMENT WILL HOST A CONFERENCE CALL AND LIVE WEBCAST TO DISCUSS THESE RESULTS AT 4:30 P.M. ET THAT SAME DAY. A QUESTION-AND-ANSWER SESSION WILL FOLLOW MANAGEMENT'S REMARKS. TO PARTIC.

EVOLUS TO REPORT FIRST QUARTER FINANCIAL RESULTS ON MAY 4, 2026

NEWPORT BEACH, CALIF.--(BUSINESS WIRE)--EVOLUS, INC. (NASDAQ: EOLS), A PERFORMANCE BEAUTY COMPANY WITH A FOCUS ON BUILDING AN AESTHETIC PORTFOLIO OF CONSUMER BRANDS, TODAY ANNOUNCED MEMBERS OF ITS MANAGEMENT TEAM WILL PARTICIPATE IN A FIRESIDE CHAT AND INVESTOR MEETINGS AT THE UPCOMING NEEDHAM VIRTUAL HEALTHCARE CONFERENCE. THE FIRESIDE CHAT WILL TAKE PLACE ON TUESDAY, APRIL 14, 2026, AT 3:45 PM ET. THE FIRESIDE CHAT CAN BE ACCESSED ON THE INVESTOR RELATIONS PAGE OF THE EVOLUS WEBSITE HERE. A R.

Evolus, Inc.

EOLS

Price

Financial Reports

No items found.

Press Releases

Evolus, Inc.

EOLS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

EOLS